Gefapixant in two randomised dose-escalation studies in chronic coughCitation formats

  • External authors:
  • Michael M Kitt
  • Peter Butera
  • Steven A Smith
  • Yuping Li
  • Zhi Jin Xu
  • Shilpi Sen
  • Mandel R Sher
  • Anthony P Ford

Standard

Gefapixant in two randomised dose-escalation studies in chronic cough. / Smith, Jacky; Kitt, Michael M ; Butera, Peter; Smith, Steven A ; Li, Yuping; Xu, Zhi Jin ; Holt, Kimberley; Sen, Shilpi; Sher, Mandel R ; Ford, Anthony P .

In: European Respiratory Journal, 16.01.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

Smith, J, Kitt, MM, Butera, P, Smith, SA, Li, Y, Xu, ZJ, Holt, K, Sen, S, Sher, MR & Ford, AP 2020, 'Gefapixant in two randomised dose-escalation studies in chronic cough', European Respiratory Journal. https://doi.org/10.1183/13993003.01615-2019

APA

Smith, J., Kitt, M. M., Butera, P., Smith, S. A., Li, Y., Xu, Z. J., Holt, K., Sen, S., Sher, M. R., & Ford, A. P. (2020). Gefapixant in two randomised dose-escalation studies in chronic cough. European Respiratory Journal. https://doi.org/10.1183/13993003.01615-2019

Vancouver

Smith J, Kitt MM, Butera P, Smith SA, Li Y, Xu ZJ et al. Gefapixant in two randomised dose-escalation studies in chronic cough. European Respiratory Journal. 2020 Jan 16. https://doi.org/10.1183/13993003.01615-2019

Author

Smith, Jacky ; Kitt, Michael M ; Butera, Peter ; Smith, Steven A ; Li, Yuping ; Xu, Zhi Jin ; Holt, Kimberley ; Sen, Shilpi ; Sher, Mandel R ; Ford, Anthony P . / Gefapixant in two randomised dose-escalation studies in chronic cough. In: European Respiratory Journal. 2020.

Bibtex

@article{76fdd625c2224a19b07fb2567e4dded5,
title = "Gefapixant in two randomised dose-escalation studies in chronic cough",
abstract = "BACKGROUND Gefapixant has previously demonstrated efficacy in the treatment refractory chronic cough at a high, daily dose. OBJECTIVES The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough using a dose escalation approach. MATERIALS AND METHODS Two randomised, double-blind, placebo-controlled, crossover, dose-escalation studies recruited participants with refractory chronic cough. Patients were assigned to receive ascending doses of gefapixant (study 1: 50-200 mg, study 2: 7.5-50 mg) or placebo for 16 days, then crossed-over after washout. The primary endpoint was awake cough frequency assessed using a 24 h ambulatory cough monitor at baseline and on day 4 of each dose. Patient reported outcomes included a cough severity visual analogue scale (VAS) and Cough Severity Diary (CSD). RESULTS In clinical studies, gefapixant doses ≥30 mg produced maximal improvements in cough frequency compared with placebo (p",
author = "Jacky Smith and Kitt, {Michael M} and Peter Butera and Smith, {Steven A} and Yuping Li and Xu, {Zhi Jin} and Kimberley Holt and Shilpi Sen and Sher, {Mandel R} and Ford, {Anthony P}",
year = "2020",
month = jan,
day = "16",
doi = "10.1183/13993003.01615-2019",
language = "English",
journal = "The European respiratory journal",
issn = "0903-1936",
publisher = "European Respiratory Society",

}

RIS

TY - JOUR

T1 - Gefapixant in two randomised dose-escalation studies in chronic cough

AU - Smith, Jacky

AU - Kitt, Michael M

AU - Butera, Peter

AU - Smith, Steven A

AU - Li, Yuping

AU - Xu, Zhi Jin

AU - Holt, Kimberley

AU - Sen, Shilpi

AU - Sher, Mandel R

AU - Ford, Anthony P

PY - 2020/1/16

Y1 - 2020/1/16

N2 - BACKGROUND Gefapixant has previously demonstrated efficacy in the treatment refractory chronic cough at a high, daily dose. OBJECTIVES The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough using a dose escalation approach. MATERIALS AND METHODS Two randomised, double-blind, placebo-controlled, crossover, dose-escalation studies recruited participants with refractory chronic cough. Patients were assigned to receive ascending doses of gefapixant (study 1: 50-200 mg, study 2: 7.5-50 mg) or placebo for 16 days, then crossed-over after washout. The primary endpoint was awake cough frequency assessed using a 24 h ambulatory cough monitor at baseline and on day 4 of each dose. Patient reported outcomes included a cough severity visual analogue scale (VAS) and Cough Severity Diary (CSD). RESULTS In clinical studies, gefapixant doses ≥30 mg produced maximal improvements in cough frequency compared with placebo (p

AB - BACKGROUND Gefapixant has previously demonstrated efficacy in the treatment refractory chronic cough at a high, daily dose. OBJECTIVES The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough using a dose escalation approach. MATERIALS AND METHODS Two randomised, double-blind, placebo-controlled, crossover, dose-escalation studies recruited participants with refractory chronic cough. Patients were assigned to receive ascending doses of gefapixant (study 1: 50-200 mg, study 2: 7.5-50 mg) or placebo for 16 days, then crossed-over after washout. The primary endpoint was awake cough frequency assessed using a 24 h ambulatory cough monitor at baseline and on day 4 of each dose. Patient reported outcomes included a cough severity visual analogue scale (VAS) and Cough Severity Diary (CSD). RESULTS In clinical studies, gefapixant doses ≥30 mg produced maximal improvements in cough frequency compared with placebo (p

U2 - 10.1183/13993003.01615-2019

DO - 10.1183/13993003.01615-2019

M3 - Article

JO - The European respiratory journal

JF - The European respiratory journal

SN - 0903-1936

ER -